selexipag

Ligand id: 7552

Name: selexipag

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 13
Topological polar surface area 109.87
Molecular weight 496.21
XLogP 6.24
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Following successful Phase III trial this compund has been approved by the US FDA for the treatment of pulmonary arterial hypertension [5]. Click here to link to ClinicalTrials.gov's complete list of selexipag trials.
Mechanism Of Action and Pharmacodynamic Effects
Prostacyclin is an endogenous vascular endothelial factor with an important role in vascular homeostasis as an inhibitor of platelet aggregation and a potent vasodilator [3]. The physiological functions are mediated by the activation of the PGI2 receptor (IP receptor) [4]. IP receptor agonists are being pursued as clinical therapeutics for control of platelet and vascular function. Selexipag is one such agonist of the PGI2 prostaglandin receptor. This action causes vasodilation in the pulmonary circulation, therby reducing pulmonary arterial blood pressure.